Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT ID: NCT03165981

Last Updated: 2024-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 221 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-25
• Study Completion Date: 2018-01-15

Brief Summary

A prospective, randomized open-label clinical trial that will be conducted during the 2017-2018 influenza season. During the 2017-2018 season, approximately 280 children will be enrolled at Duke University Medical Center and Kaiser Permanente Northern California. Eligible children will be randomized to receive simultaneous or sequentially administered US licensed PCV13, US-licensed DTaP vaccine, and US-licensed inactivated influenza vaccine (IIV). Children in the simultaneous group will receive PCV13, DTaP, and IIV vaccines at Visit 1, and then return for a health education visit without vaccination about 2 weeks later (Visit 2). Children in the sequential group will receive both PCV13 and DTaP without IIV at Visit 1, and then will receive IIV and health education about 2 weeks later (Visit 2). Parents will record the occurrence of fever, solicited adverse events, medical care utilization, and receipt of antipyretics over 8 days following Visit 1 and Visit 2. In addition, febrile seizures and serious adverse events will be recorded for the entire study period (from enrollment through 8 days following the Visit 2) as determined through parental report and chart review. Parental perceptions about their child's vaccine schedule will be assessed on the 8th day following Visit 2.

Conditions

Fever After Vaccination; Fever; Febrile Seizure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Simultaneous vaccination arm

In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.

Group Type: OTHER

PCV13

Intervention Type: BIOLOGICAL

ACIP Recommended vaccine

DTaP

Intervention Type: BIOLOGICAL

ACIP Recommended vaccine

IIV

Intervention Type: BIOLOGICAL

ACIP Recommended vaccine

Sequential vaccination arm

In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.

Group Type: OTHER

PCV13

Intervention Type: BIOLOGICAL

ACIP Recommended vaccine

DTaP

Intervention Type: BIOLOGICAL

ACIP Recommended vaccine

IIV

Intervention Type: BIOLOGICAL

ACIP Recommended vaccine

Interventions

PCV13

ACIP Recommended vaccine

Intervention Type: BIOLOGICAL

DTaP

ACIP Recommended vaccine

Intervention Type: BIOLOGICAL

IIV

ACIP Recommended vaccine

Intervention Type: BIOLOGICAL

Other Intervention Names

13-valent Conjugate Pneumococcal Vaccine; Diphtheria, Tetanus, and Acellular Pertussis Vaccine; Quadrivalent Inactivated Influenza Vaccine; IIV4; Flu Vaccine

Eligibility Criteria

Inclusion Criteria

1. 12 through 16 months of age (i.e. from the 1-year birthday until the day before 17 months of age) at the time of vaccination

2. Stable health as determined by investigator's clinical examination and assessment of child's medical history

3. Has received all immunizations recommended by Advisory Committee for Immunization Practices (ACIP) during the first year of life with the exception of rotavirus and influenza vaccines.

4. The parent(s)/ legally authorized representative(s) LAR(s) intend for the child to receive DTaP and PCV13 in addition to this season's IIV

5. The parent(s)/LAR(s) must be willing and capable of providing permission for their child to participate through the written informed consent process

6. The parent(s)/LAR(s) must be able to comply with the requirements of the protocol (e.g., completion of the memory aid (either electronic or paper diary), return for follow-up visits, respects intervals between the visits and have telephone access.

7. The parent(s)/LAR(s) must be English speaking

8. The parent(s)/LAR(s) must agree to sign a medical release for the child so that study personnel may obtain medical information about the child's health (if needed)

Exclusion Criteria

1. History of any seizure (including febrile seizure) in the child or a febrile seizure in a first degree relative

2. Has already completed influenza vaccination during the current season per ACIP recommendations

3. Receipt of more than 3 previous doses of DTaP

4. Received the 3rd dose of DTaP within 6 months of Visit 1

5. Receipt of more than 3 previous doses of PCV13

6. Received the 3rd dose of PCV13 within 8 weeks of Visit 1

7. History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any influenza, diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or pneumococcal vaccine.

8. History of a severe allergic reaction (e.g., anaphylaxis) to any component (including egg protein) of any of the three vaccines used in this study; or a latex allergy.

9. History of Guillain-Barré syndrome within 6 weeks following a prior dose of influenza, DTaP, or tetanus toxoid containing vaccine

10. History of a progressive neurologic disorder

11. History of encephalopathy within 7 days of a previous pertussis-containing vaccine

12. History of collapse within 3 days after a prior dose of DTaP

13. Received any other licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Visit 1

14. Received an experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 28 days prior to Visit 1, or expects to receive an experimental/investigational agent during the study period (up to 8 days after visit 2)

15. A moderate to severe acute illness within 72 hours of Visit 1

16. A reported temperature greater than or equal to 100.4°F (38.0°C) within 72 hours prior enrollment or a temperature (measured by temporal artery thermometer) greater than or equal to 100.4°F (38.0°C) at the time of enrollment

17. Receipt of an antipyretic medication (acetaminophen or ibuprofen) within 24 hours prior to enrollment

18. Parent(s)/LAR is planning to administer a prophylactic antipyretic or medication on the day of, and/or within 7 days following Visit 1 or Visit 2

19. Long term (at least 14 consecutive days) oral corticosteroids (prednisone 2 mg/kg/day or equivalent other glucocorticoid), any parenteral steroids, high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) or other immune-modifying drugs or immunosuppressants within the preceding 6 months prior to Visit 1

20. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and or their provider's routine physical examination

21. Has an active neoplastic disease, a history of any hematologic malignancy, current bleeding disorder, or taking anticoagulants.

22. Unable to receive an intramuscular injection in the thigh

23. Any condition deemed by the investigator to place the child at increased risk as a result of their participation in the study

24. Any child or grandchild of a study investigator or study team member

• Minimum Eligible Age: 12 Months
• Maximum Eligible Age: 16 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Centers for Disease Control and Prevention

FED

Sponsor Role: collaborator

Kaiser Permanente

OTHER

Sponsor Role: collaborator

Duke University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Emmanuel B Walter, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Duke University

Karen Broder, MD

Role: PRINCIPAL_INVESTIGATOR

Centers for Disease Control and Prevention

Nicola Klein, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Kaiser Permanente

Locations

Kaiser Permanente Northern California

Oakland, California, United States

Centers for Disease Control and Prevention

Atlanta, Georgia, United States

Duke University

Durham, North Carolina, United States

Countries

United States

References

Walter EB, Klein NP, Wodi AP, Rountree W, Todd CA, Wiesner A, Duffy J, Marquez PL, Broder KR. Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations. Pediatrics. 2020 Mar;145(3):e20191909. doi: 10.1542/peds.2019-1909. Epub 2020 Feb 6.

Reference Type: DERIVED

PMID: 32029684 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

200 2012 53663 0009

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

Pro00082484

Identifier Type: -

Identifier Source: org_study_id